Literature DB >> 15365615

Population-based stepwise screening for unrecognised Type 2 diabetes is ineffective in general practice despite reliable algorithms.

J O Christensen1, A Sandbaek, T Lauritzen, K Borch-Johnsen.   

Abstract

AIMS/HYPOTHESIS: The yield of screening programmes for Type 2 diabetes in the existing healthcare setting might be lower than anticipated from tests of screening algorithms in data from epidemiological surveys. Our aims were to evaluate the reliability of the algorithms and the effectiveness of a proposed stepwise screening programme for Type 2 diabetes in general practice.
METHODS: The screening programme had four steps: (i) mail-distributed self-administered risk-chart; (ii) screening tests: random blood glucose (RBG) and HbA(1)c; (iii) diagnostic procedure 1 for fasting blood glucose (FBG) (if RBG >/=5.5 mmol/l or HbA(1)c >/=6.1%); and (iv) OGTT as diagnostic procedure 2 (if 5.6</=FBG<6.1 mmol/l or HbA(1)c >/=6.1%). Abnormalities of glucose metabolism were classified according to the WHO 1999 criteria, based on capillary whole blood. The subjects were all patients between 40 and 69 years of age ( n=60,926) who were registered in 88 general practices and had not been previously diagnosed with diabetes.
RESULTS: A total of 11,263 individuals had a high-risk risk-score and attended the screening consultation (step 1 test-positive). Of these, 30.1% needed diagnostic tests (step 2 test-positive) and 27.2% of these needed an OGTT (step 3 test-positive). The test-positive proportions were equal to the proportions obtained in data from a population-based survey from Step 2 onwards, and the algorithms were thus reliable. The identification rate was only 19% of all prevalent undiagnosed diabetes according to a recently published prevalence estimate. This was due to a large dropout rate among high-risk individuals prior to entry into the programme. CONCLUSIONS/
INTERPRETATION: Population-based mail-distributed stepwise screening for Type 2 diabetes in general practice is ineffective, despite reliable screening algorithms, primarily because many high-risk individuals fail to participate.

Entities:  

Mesh:

Year:  2004        PMID: 15365615     DOI: 10.1007/s00125-004-1496-2

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  17 in total

1.  Performance of a predictive model to identify undiagnosed diabetes in a health care setting.

Authors:  C A Baan; J B Ruige; R P Stolk; J C Witteman; J M Dekker; R J Heine; E J Feskens
Journal:  Diabetes Care       Date:  1999-02       Impact factor: 19.112

2.  Increasing prevalence of diabetes mellitus and impaired glucose tolerance among 60-year-old Danes.

Authors:  T Drivsholm; H Ibsen; M Schroll; M Davidsen; K Borch-Johnsen
Journal:  Diabet Med       Date:  2001-02       Impact factor: 4.359

3.  Using the World Wide Web--a new approach to risk identification of diabetes mellitus.

Authors:  T U Baehring; H Schulze; S R Bornstein; W A Scherbaum
Journal:  Int J Med Inform       Date:  1997-08       Impact factor: 4.046

4.  Screening for diabetes mellitus in high-risk patients: cost, yield, and acceptability.

Authors:  P J O'Connor; W A Rush; L M Cherney; N P Pronk
Journal:  Eff Clin Pract       Date:  2001 Nov-Dec

5.  Performance characteristics of the HemoCue B-Glucose analyzer using whole-blood samples.

Authors:  E M Voss; G S Cembrowski
Journal:  Arch Pathol Lab Med       Date:  1993-07       Impact factor: 5.534

6.  A new and simple questionnaire to identify people at increased risk for undiagnosed diabetes.

Authors:  W H Herman; P J Smith; T J Thompson; M M Engelgau; R E Aubert
Journal:  Diabetes Care       Date:  1995-03       Impact factor: 19.112

7.  Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 study.

Authors:  Charlotte Glümer; Torben Jørgensen; Knut Borch-Johnsen
Journal:  Diabetes Care       Date:  2003-08       Impact factor: 19.112

8.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

9.  Diabetic patients detected by population-based stepwise screening already have a diabetic cardiovascular risk profile.

Authors:  Annemieke M W Spijkerman; Marcel C Adriaanse; Jacqueline M Dekker; Giel Nijpels; Coen D A Stehouwer; Lex M Bouter; Robert J Heine
Journal:  Diabetes Care       Date:  2002-10       Impact factor: 19.112

10.  Performance of an NIDDM screening questionnaire based on symptoms and risk factors.

Authors:  J B Ruige; J N de Neeling; P J Kostense; L M Bouter; R J Heine
Journal:  Diabetes Care       Date:  1997-04       Impact factor: 19.112

View more
  36 in total

1.  Screening for diabetes using an oral glucose tolerance test within a western multi-ethnic population identifies modifiable cardiovascular risk: the ADDITION-Leicester study.

Authors:  D R Webb; L J Gray; K Khunti; B Srinivasan; N Taub; S Campbell; J Barnett; A Farooqi; J B Echouffo-Tcheugui; S J Griffin; N J Wareham; M J Davies
Journal:  Diabetologia       Date:  2011-06-03       Impact factor: 10.122

2.  Risk scores for predicting type 2 diabetes: using the optimal tool.

Authors:  M Alssema; D Vistisen; M W Heymans; G Nijpels; C Glümer; P Z Zimmet; J E Shaw; M Eliasson; C D A Stehouwer; A G Tabák; S Colagiuri; K Borch-Johnsen; J M Dekker
Journal:  Diabetologia       Date:  2011-06-10       Impact factor: 10.122

3.  Screening and identifying diabetes in optometric practice: a prospective study.

Authors:  Jennifer H Howse; Steve Jones; A Pali S Hungin
Journal:  Br J Gen Pract       Date:  2011-07       Impact factor: 5.386

4.  HbA1c and cardiovascular risk score identify people who may benefit from preventive interventions: a 7 year follow-up of a high-risk screening programme for diabetes in primary care (ADDITION), Denmark.

Authors:  T Lauritzen; A Sandbaek; M V Skriver; K Borch-Johnsen
Journal:  Diabetologia       Date:  2011-02-22       Impact factor: 10.122

5.  Psychological distress, cardiovascular complications and mortality among people with screen-detected type 2 diabetes: follow-up of the ADDITION-Denmark trial.

Authors:  Else-Marie Dalsgaard; Mogens Vestergaard; Mette V Skriver; Helle T Maindal; Torsten Lauritzen; Knut Borch-Johnsen; Daniel Witte; Annelli Sandbaek
Journal:  Diabetologia       Date:  2014-01-18       Impact factor: 10.122

6.  The Impact of the Affordable Care Act (ACA) Medicaid Expansion on Visit Rates for Diabetes in Safety Net Health Centers.

Authors:  Nathalie Huguet; Rachel Springer; Miguel Marino; Heather Angier; Megan Hoopes; Heather Holderness; Jennifer E DeVoe
Journal:  J Am Board Fam Med       Date:  2018 Nov-Dec       Impact factor: 2.657

7.  Effect of screening for type 2 diabetes on healthcare costs: a register-based study among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009.

Authors:  Camilla Sortsø; Anastasija Komkova; Annelli Sandbæk; Simon J Griffin; Martha Emneus; Torsten Lauritzen; Rebecca K Simmons
Journal:  Diabetologia       Date:  2018-03-16       Impact factor: 10.122

8.  General effect on high-risk persons when general practitioners are trained in intensive treatment of type 2 diabetes.

Authors:  Signe S Rasmussen; Charlotte Glümer; Annelli Sandbaek; Torsten Lauritzen; Knut Borch-Johnsen
Journal:  Scand J Prim Health Care       Date:  2008       Impact factor: 2.581

9.  Adherence to guidelines in people with screen-detected type 2 diabetes, ADDITION, Denmark.

Authors:  Lise Juul; Annelli Sandbaek; Anders Foldspang; Morten Frydenberg; Knut Borch-Johnsen; Torsten Lauritzen
Journal:  Scand J Prim Health Care       Date:  2009       Impact factor: 2.581

10.  General practitioners' adherence to guidelines on management of dyslipidaemia: ADDITION-Denmark.

Authors:  Lise Graversen; Bo Christensen; Knut Borch-Johnsen; Torsten Lauritzen; Annelli Sandbaek
Journal:  Scand J Prim Health Care       Date:  2010-03       Impact factor: 2.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.